Skip to main content
SpringerLink
Log in

Dendritic Cell-Based Vaccines for Cancer Therapy

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296.

    PubMed  CAS  Google Scholar 

  2. Austyn, J. M. 1996. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 183:1287–1292.

    PubMed  CAS  Google Scholar 

  3. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245–252.

    PubMed  CAS  Google Scholar 

  4. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405–411.

    PubMed  CAS  Google Scholar 

  5. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693–1702.

    PubMed  CAS  Google Scholar 

  6. Vecchi, A., L. Massimiliano, S. Ramponi, W. Luini, S. Bernasconi, R. Bonecchi, P. Allavena, M. Parmentier, A. Mantovani, and S. Sozzani. 1999. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol 66:489–494.

    PubMed  CAS  Google Scholar 

  7. Zhang, Y., A. Harada, J. B. Wang, Y. Y. Zhang, S. Hashimoto, M. Naito, and K. Matsushima. 1998. Bifurcated dendritic cell differentiation in vitro from murine lineage phenotype-negative c-kit+ bone marrow hematopoietic progenitor cells. Blood 92:118–128.

    PubMed  CAS  Google Scholar 

  8. Fields, R. C., K. Shimizu, and J. J. Mulé. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482–9487.

    PubMed  CAS  Google Scholar 

  9. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97.

    PubMed  CAS  Google Scholar 

  10. Shimizu, K., E. K. Thomas, M. Giedlin, and J. J. Mulé. 2001. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 61:2618–2624.

    PubMed  CAS  Google Scholar 

  11. Nair, S. K., D. Snyder, B. T. Rouse, and E. Gilboa. 1997. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70:706–715.

    PubMed  CAS  Google Scholar 

  12. Nair, S. K., D. Boczkowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589–597.

    PubMed  CAS  Google Scholar 

  13. Ribas, A., L. A. Bui, L. H. Butterfield, C. M. Vollmer, S. M. Jilani, V. B. Dissette, J. A. Glaspy, W. H. McBride, and J. S. Economou. 1999. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 19:1165–1170.

    PubMed  CAS  Google Scholar 

  14. Gatza, E., and C. Y. Okada. 2002. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 169:5227–5235.

    PubMed  Google Scholar 

  15. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605–610.

    PubMed  CAS  Google Scholar 

  16. Zhou, Y., M. L. Bosch, and M. L. Salgaller. 2002. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25:289–303.

    PubMed  CAS  Google Scholar 

  17. Eggert, A. A., M. W. Schreurs, O. C. Boerman, W. J. Oyen, A. J. de Boer, C. J. Punt, C. G. Figdor, and G. J. Adema. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. J Exp Med 169:1169–1178.

    Google Scholar 

  18. Fong, L., D. Brockstedt, C. Benike, L. Wu, and E. G. Engleman. 2001. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166:4254–4259.

    PubMed  CAS  Google Scholar 

  19. Tuting, T., J. Steitz, J. Bruck, A. Gambotto, K. Steinbrink, A. B. DeLeo, P. Robbins, J. Knop, and A. H. Enk. 1999. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1:400–406.

    PubMed  CAS  Google Scholar 

  20. Kaplan, J. M., Q. Yu, S. T. Piraino, S. E. Pennington, S. Shankara, L. A. Woodworth, and B. L. Roberts. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699–707.

    PubMed  CAS  Google Scholar 

  21. Melero, I., M. Duarte, J. Ruiz, B. Sangro, J. Galofre, G. Mazzolini, M. Bustos, C. Qian, and J. Prieto. 1999. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6:1779–1784.

    PubMed  CAS  Google Scholar 

  22. Xia, D. J., W. P. Zhang, S. Zheng, J. Wang, J. P. Pan, Q. Wang, L. H. Zhang, H. Hamada, and X. Cao. 2002. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther 9:592–601.

    PubMed  CAS  Google Scholar 

  23. Willimann, K., D. F. Legler, M. Loetscher, R. S. Roos, M. B. Delgado, I. Clark-Lewis, and M. Baggiolini. 1998. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28:2025–2034.

    PubMed  CAS  Google Scholar 

  24. Campbell, J. J., E. P. Bowman, K. Murphy, K. R. Youngman, M. A. Siani, D. A. Thompson, L. Wu, A. Zlotnik, and E. C. Butcher. 1998. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3b receptor CCR7. J Cell Biol 141:1053–1059.

    PubMed  CAS  Google Scholar 

  25. Kirk, C. J., D. Hartigan-O’Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mulé. 2001. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062–2070.

    PubMed  CAS  Google Scholar 

  26. Kirk, C. J., D. Hartigan-O’Connor, and J. J. Mulé. 2001. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61:8794–8802.

    PubMed  CAS  Google Scholar 

  27. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549.

    PubMed  CAS  Google Scholar 

  28. Coombes, B. K., and J. B. Mahony. 2001. Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. Immunol Lett 78:103–111.

    PubMed  CAS  Google Scholar 

  29. Weiner, G. J., H. M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94:10833–10837.

    PubMed  CAS  Google Scholar 

  30. Brunner, C., J. Seiderer, A. Schlamp, M. Bidlingmaier, A. Eigler, W. Haimerl, H. A. Lehr, A. M. Krieg, G. Hartmann, and S. Endres. 2000. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165:6278–6286.

    PubMed  CAS  Google Scholar 

  31. Zitvogel, L., A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo, and S. Amigorena. 1998. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4:594–600.

    PubMed  CAS  Google Scholar 

  32. Schartz, N. E., N. Chaput, F. Andre, and L. Zitvogel. 2002. From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Curr Opin Mol Ther 4:372–381.

    PubMed  CAS  Google Scholar 

  33. Wolfers, J., A. Lozier, G. Raposo, A. Regnault, C. Thery, C. Masurier, C. Flament, S. Pouzieux, F. Faure, T. Tursz, E. Angevin, S. Amigorena, and L. Zitvogel. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7:297–303.

    PubMed  CAS  Google Scholar 

  34. Thery, C., M. Boussac, P. Veron, P. Ricciardi-Castagnoli, G. Raposo, J. Garin, and S. Amigorena. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166:7309–7318.

    PubMed  CAS  Google Scholar 

  35. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558–561.

    PubMed  CAS  Google Scholar 

  36. Celluzzi, C. M., and L. D. Jr. Falo. 1998. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 160:3081–3085.

    PubMed  CAS  Google Scholar 

  37. Wang, J., S. Saffold, X. Cao, J. Krauss, and W. Chen. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516–5524.

    PubMed  CAS  Google Scholar 

  38. McConnell, E. J., L. B. Pathangey, C. S. Madsen, S. J. Gendler, and P. Mukherjee. 2002. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res 107:196–202.

    PubMed  CAS  Google Scholar 

  39. Gong, J., S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe. 2002. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512–2517.

    PubMed  CAS  Google Scholar 

  40. Lindner, M., and V. Schirrmacher. 2002. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylenglycol versus electro-fusion protocols. Eur J Clin Invest 32:207–217.

    PubMed  Google Scholar 

  41. Hayashi, T., H. Tanaka, J. Tanaka, R. Wang, B. J. Averbook, P. A. Cohen, and S. Shu. 2002. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14–20.

    PubMed  CAS  Google Scholar 

  42. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625–631.

    PubMed  CAS  Google Scholar 

  43. Zeis, M., T. Zunkel, J. Steinmann, N. Schmitz, and L. Uharek. 2002. Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma. Br J Haematol 117:93–102.

    PubMed  CAS  Google Scholar 

  44. Pawlowska, A. B., S. Hashino, H. McKenna, B. J. Weigel, P. A. Taylor, and B. R. Blazar. 2001. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97:1474–1482.

    PubMed  CAS  Google Scholar 

  45. Akasaki, Y., T. Kikuchi, S. Homma, T. Abe, D. Kofe, and T. Ohno. 2001. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106–113.

    CAS  Google Scholar 

  46. Ashley, D. M., B. Faiola, S. Nair, L. P. Hale, D. D. Bigner, and E. Gilboa. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177–1182.

    PubMed  CAS  Google Scholar 

  47. Aoki, H., M. Mizuno, A. Natsume, T. Tsugawa, K. Tsujimura, T. Takahashi, and J. Yoshida. 2001. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463–468.

    PubMed  CAS  Google Scholar 

  48. Heimberger, A. B., L. E. Crotty, G. E. Archer, R. E. McLendon, A. Friedman, G. Dranoff, D. D. Bigner, and J. H. Sampson. 2000. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16–25.

    PubMed  CAS  Google Scholar 

  49. Ni, H. T., S. R. Spellman, W. C. Jean, W. A. Hall, and W. C. Low. 2001. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9.

    PubMed  CAS  Google Scholar 

  50. Sloan, A. E., and P. Parajuli. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity. J Neurooncol (in press).

    Google Scholar 

  51. Yoshida, S., K. Morii, M. Watanabe, T. Saito, K. Yamamoto, and R. Tanaka. 2001. The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors. Cancer Immunol Immunother 50:321–327.

    PubMed  CAS  Google Scholar 

  52. Liau, L. M., K. L. Black, R. M. Prins, S. N. Sykes, P. L. DiPatre, T. F. Cloughesy, D. P. Becker, and J. M. Bronstein. 1999. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124.

    PubMed  CAS  Google Scholar 

  53. Broder, H., A. Anderson, S. K. Odesa, T. J. Kremen, and L. M. Liau. 2000. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurg Focus 9:Article 6.

    Google Scholar 

  54. Okada, H., H. Tahara, M. R. Shurin, J. Attanucci, K. M. Giezeman-Smits, W. K. Fellows, M. T. Lotze, W. H. Chambers, and M. E. Bozik. 1998. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196–201.

    PubMed  CAS  Google Scholar 

  55. Yamanaka, R., S. A. Zullo, R. Tanaka, M. Blaese, and K. G. Xanthopoulos. 2001. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94:474–481.

    PubMed  CAS  Google Scholar 

  56. Yamanaka, R., S. A. Zullo, J. Ramsey, N. Yajima, N. Tsuchiya, R. Tanaka, M. Blaese, and K. G. Xanthopoulos. 2002a. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 97:611–618.

    PubMed  CAS  Google Scholar 

  57. Yamanaka, R., N. Yajima, N. Tsuchiya, J. Honma, R. Tanaka, J. Ramsey, M. Blaese, and K. G. Xanthopoulos. 2002b. Administration of interleukin-12 and-18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J Neurosurg 97:1184–1190.

    PubMed  CAS  Google Scholar 

  58. Insug, O., G. Ku, H. C. Ertl, and M. Blaszczyk-Thurin. 2002. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613–621.

    PubMed  CAS  Google Scholar 

  59. Witham, T. F., M. L. Erff, H. Okada, W. H. Chambers, and I. F. Pollack. 2002. Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50:1327–1335.

    PubMed  Google Scholar 

  60. Yang, T., T. F. Witham, L. Villa, M. Erff, J. Attanucci, S. Watkins, D. Kondziolka, H. Okada, I. F. Pollack, and W. H. Chambers. 2002. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 62:2583–2591.

    PubMed  CAS  Google Scholar 

  61. Candido, K. A., K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé. 2001. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis inducing agents. Cancer Res 1:228–236.

    Google Scholar 

  62. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor alpha. J Exp Med 179:1109–1118.

    PubMed  CAS  Google Scholar 

  63. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137–151.

    PubMed  CAS  Google Scholar 

  64. Strobl, H., C. Bello-Fernandez, E. Riedl, W. F. Pickl, O. Majdic, S. D. Lyman, and W. Knapp. 1997. Flt3 ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425–1434.

    PubMed  CAS  Google Scholar 

  65. Berger, T. G., B. Feuerstein, E. Strasser, U. Hirsch, D. Schreiner, G. Schuler, and B. Schuler-Thurner. 2002. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 268:131–140.

    PubMed  CAS  Google Scholar 

  66. Pullarkat, V., R. Lau, S. M. Lee, J. G. Bender, and J. S.Weber. 2002. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 267:173–183.

    PubMed  CAS  Google Scholar 

  67. Fong, L., D. Brockstedt, C. Benike, J. K. Breen, G. Strang, C. L. Ruegg, and E. G. Engleman. 2002. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167:7150–7156.

    Google Scholar 

  68. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58.

    PubMed  CAS  Google Scholar 

  69. Mehta-Damani, A., S. Markowicz, and E. G. Engleman. 1995. Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol 25:1206–1211.

    PubMed  CAS  Google Scholar 

  70. Mehta-Damani, A., S. Markowicz, and E. G. Engleman. 1994. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 153:996–1003.

    PubMed  CAS  Google Scholar 

  71. Bernhard, H., M. L. Disis, S. Heimfeld, S. Hand, J. R. Gralow, and M. A. Cheever. 1995. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099–1104.

    PubMed  CAS  Google Scholar 

  72. Sato, K., H. Nagayama, and T. A. Takahashi. 1998. Generation of dendritic cells from fresh and frozen cord blood CD34+ cells. Cryobiology 37:362–371.

    PubMed  CAS  Google Scholar 

  73. Siena, S., M. D. Nicola, M. Bregni, R. Mortarini, A. Anichini, L. Lombardi, F. Ravagnani, G. Parmiani, and A. M. Gianni. 1995. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 23:1463–1471.

    PubMed  CAS  Google Scholar 

  74. Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-Vis, C. Jacquet, K. Yoneda, S. Imamura, D. Schmitt, and J. Banchereau. 1996. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF-alpha. J Exp Med 184:695–706.

    PubMed  CAS  Google Scholar 

  75. Young, J. W., P. Szabolcs, and M. A. Moore. 1995. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 182:1111–1119.

    PubMed  CAS  Google Scholar 

  76. Mortarini, R., A. Anichini, M. D. Nicola, S. Siena, M. Bregni, F. Belli, A. Molla, A. M. Gianni, and G. Parmiani. 1997. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57:5534–5541.

    PubMed  CAS  Google Scholar 

  77. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, I. Durand, M. Cella, A. Lanzavecchia, and J. Banchereau. 1997. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor. II. Functional analysis. Blood 90:1458–1470.

    PubMed  CAS  Google Scholar 

  78. Maraskovsky, E., E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J. Hoek, D. Caron, M. E. Lebsack, and H. J. McKenna. 2000. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:878–884.

    PubMed  CAS  Google Scholar 

  79. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809–8814.

    PubMed  CAS  Google Scholar 

  80. Thurner, B., C. Roder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kampgen, A. Bender, and G. Schuler. 1999a. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1–15.

    PubMed  CAS  Google Scholar 

  81. Winzler, C., P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V. S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 185:317–328.

    PubMed  CAS  Google Scholar 

  82. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183–1187.

    PubMed  CAS  Google Scholar 

  83. Lotze, M. T., H. Farhood, C. W. Wilson, and W. J. Storkus. 1999. Dendritic cell therapy of cancer and HIV infection. In Dendritic Cells: Biology and Clinical Applications. T.A. Lotze, M.T., ed. Academic Press, San Diego, CA: 459–485.

    Google Scholar 

  84. Dhodapkar, M.W., R. M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238.

    PubMed  CAS  Google Scholar 

  85. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213–1222.

    PubMed  CAS  Google Scholar 

  86. Schott, M., J. Seissler, M. Lettmann, V. Fouxon, W. A. Scherbaum, and J. Feldkamp. 2001. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab 86:4965–4969.

    PubMed  CAS  Google Scholar 

  87. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. Von Den Driesch, E. B. Brocker, R. M. Steinman, A. Enk, E. Kampgen, and G. Schuler. 1999b. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678.

    PubMed  CAS  Google Scholar 

  88. De Vries, J. J., A. A. Eggert, N. M. Scharenborg, J. L. Vissers, W. J. Lesterhuis, O. C. Boerman, C. J. Punt, G. J. Adema, and C. G. Fidgor. 2002. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 25:429–438.

    PubMed  Google Scholar 

  89. De Vries, I. J., D. J. Krooshoop, N. M. Scharenborg, W. J. Lesterhuis, J. H. Diepstra, G. N. Van Muijen, S. P. Strijk, T. J. Ruers, O. C. Boerman, W. J. Oyen, G. J. Adema, C. J. Punt, and C. G. Fidgor. 2003. Effective migration of antigen-pulsed dendritic cells to lymph node in melanoma patients is determined by thier maturation state. Cancer Res 63:12–17.

    PubMed  Google Scholar 

  90. Dhodapkar, M. V., R. M. Steinam, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S. M. Donahoe, P. R. Dunbar, V. Cerundolo, D. F. Nixon, and N. Bhardwaj. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104:173–180.

    PubMed  CAS  Google Scholar 

  91. Jonuleit, H., A. Giesecke-Tuettenberg, T. Tuting, B. Thurner-Sculer, T. B. Stuge, L. Paragnik, A. Kandemir, P. P. Lee, G. Schuler, J. Knop, and A. H. Enk. 2001. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243–251.

    PubMed  CAS  Google Scholar 

  92. Luft, T., M. Jefford, P. Luetjens, T. Toy, H. Hochrein, K. A. Masterman, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific D subsets. Blood 100:1362–1372.

    PubMed  CAS  Google Scholar 

  93. Mukherji, B., N. G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J. R. Sporn, S. K. Kurtzman, M. T. Ergin, J. Ozols, J. Meehan, and F. Mauri. 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A 92:8078–8082.

    PubMed  CAS  Google Scholar 

  94. Schuler-Thurner, B., D. Dieckmann, P. Keikavoussi, A. Bender, C. Maczek, H. Jonuleit, C. Roder, I. Haendle, W. Leisgang, R. Dunbar, V. Cerundolo, P. Von Den Driesch, J. Knop, E. B. Brocker, A. Enk, E. Kampgen, and G. Schuler. 2000. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492–3496.

    PubMed  CAS  Google Scholar 

  95. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. D. G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332.

    PubMed  CAS  Google Scholar 

  96. Romero, P., V. Dutoit, V. Rubio-Godoy, D. Lienard, D. Speiser, P. Guillaume, K. Servis, D. Rimoldi, J. C. Cerottini, and D. Valmori. 2001. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res 7:766s–772s.

    PubMed  CAS  Google Scholar 

  97. Rivoltini, L., P. Squarcina, D. J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, V. Viggiano, F. Belli, and G. Parmiani. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 59:301–306.

    PubMed  CAS  Google Scholar 

  98. Jager, E., D. Jager, and A. Knuth. 2002. Clinical cancer vaccine trials. Curr Opin Immunol 14:178–182.

    PubMed  CAS  Google Scholar 

  99. Mackensen, A., B. Herbst, J. L. Chen, G. Kohler, C. Noppen, W. Herr, G. C. Spagnoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385–392.

    PubMed  CAS  Google Scholar 

  100. Geiger, J. D., R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mulé. 2001. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513–8519.

    PubMed  CAS  Google Scholar 

  101. Chang, A. E., B. G. Redman, J. R. Whitfield, B. J. Nickoloff, T. M. Braun, P. P. Lee, J. D. Geiger, and J. J. Mulé. 2002. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8:1021–1032.

    PubMed  CAS  Google Scholar 

  102. Nair, S. K., S. Hull, D. Coleman, E. Gilboa, H. K. Lyerly, and M. A. Morse. 1999. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 82:121–124.

    PubMed  CAS  Google Scholar 

  103. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class-I restricted CTLs. Nature 392:86–89.

    PubMed  CAS  Google Scholar 

  104. Jenne, L., J. F. Arrighi, H. Jonuleit, J. H. Saurat, and C. Hauser. 2000. Dendritic cells containing apoptotic melanoma cells prime human CD8+T cells for efficient tumor cell lysis. Cancer Res 60:4446–4452.

    PubMed  CAS  Google Scholar 

  105. Kurokawa, T., M. Oelke, and A. Mackensen. 2001. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 91:749–756.

    PubMed  CAS  Google Scholar 

  106. Kikuchi, T., Y. Akasaki, M. Irie, S. Homma, T. Abe, and T. Ohno. 2001. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344.

    PubMed  CAS  Google Scholar 

  107. Trefzer, U., G. Weingart, Y. Chen, G. Herberth, K. Adrian, H. Winter, H. Audring, Y. Guo, W. Sterry, and P. Walden. 2000. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85:618–626.

    PubMed  CAS  Google Scholar 

  108. Timmerman, J. M., D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, A. van Beckhoven, T. M. Liles, E. G. Engleman, and R. Levy. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526.

    PubMed  CAS  Google Scholar 

  109. Lim, S. H., and R. Bailey-Wood. 1999. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 83:215–222.

    PubMed  CAS  Google Scholar 

  110. Reichardt, V. L., C. Y. Okada, A. Liso, C. J. Benike, K. E. Stockerl-Goldstein, E. G. Engleman, K. G. Blume, and R. Levy. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93:2411–2419.

    PubMed  CAS  Google Scholar 

  111. Titzer, S., O. Christensen, O. Manzke, H. Tesch, J. Wolf, B. Emmerich, C. Carsten, V. Diehl, and H. Bohlen. 2000. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 108:805–816.

    PubMed  CAS  Google Scholar 

  112. Arthur, J., L. Butterfield, M. Roth, L. Bui, S. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. McBride, and J. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17–25.

    PubMed  CAS  Google Scholar 

  113. Kirk, C. J., and J. J. Mulé. 2000. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11:797–806.

    PubMed  CAS  Google Scholar 

  114. Jenne, L., G. Schuler, and A. Steinkasserer. 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102–107.

    PubMed  CAS  Google Scholar 

  115. Skinner, P., and A. T. Haase. 2002. In situ tetramer staining. J Immunol Methods 268:29–34.

    PubMed  CAS  Google Scholar 

  116. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96.

    PubMed  CAS  Google Scholar 

  117. Housseau, F., K. R. Lindsey, S. D. Oberholtzer, M. I. Gonzales, P. Boutin, A. K. Moorthy, S. Shankara, B. L. Roberts, and S. L. Topalian. 2002. Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. J Immunol Methods 266:87–103.

    PubMed  CAS  Google Scholar 

  118. Rini, B. I., A. Paintal, N. J. Vogelzang, T. F. Gajewski, and W. M. Stadler. 2002. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother 25:269–277.

    PubMed  CAS  Google Scholar 

  119. Liau, L. M., K. L. Black, N. A. Martin, S. N. Sykes, J. M. Bronstein, L. Jouben-Steele, P. S. Mischel, A. Belldegrun, and T. F. Cloughesy. 2000. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatability complex class I-matched tumor peptides. Neurosurg Focus 9:Article 8.

    Google Scholar 

  120. Yu, J. S., C. J. Wheeler, P. M. Zeltzer, H. Ying, D.N. Finger, P. K. Lee, W. H. Yong, F. Incardona, R. C. Thompson, M. S. Riedinger, W. Zhang, R. M. Prins, and K. L. Black. 2001. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 6:842–847.

    Google Scholar 

  121. Okada, H., I. F. Pollack, F. Lieberman, L. D. Lunsford, D. Kondziolka, D. Schiff, J. Attanucci, H. Edington, W. Chambers, P. Kalinski, D. Kinzler, T. Whiteside, E. Elder, and D. Potter. 2001. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts toelicit an immune response. Hum Gene Ther 12:575–595.

    PubMed  CAS  Google Scholar 

  122. Bigner, D. D., O. M. Pitts, and C. J. Wikstrand. 1981. Induction of lethal experimental autoimmune encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 55:32–42.

    PubMed  CAS  Google Scholar 

  123. Liau, L. M. 2002. DC-immunotherapy of malignant gliomas: preliminary results. In Platform Presentation, Society of Neuro-Oncology, November 23, San Diego, CA.

    Google Scholar 

  124. Mackensen, A., B. Herbst, J. L. Chen, G. Kohler, C. Noppen, W. Herr, G.C. Spanoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulse dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385–392.

    PubMed  CAS  Google Scholar 

  125. Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56–58.

    PubMed  CAS  Google Scholar 

  126. Panelli, M. C., J. Wunderlich, J. Jeffries, E. Wang, A. Mixon, S. A. Rosenberg, and F. M. Marincola. 2000. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23:487–498.

    PubMed  CAS  Google Scholar 

  127. Toungouz, M., M. Libin, F. Bulte, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman, and T. Velu. 2001. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 69:937–943.

    PubMed  CAS  Google Scholar 

  128. Gajewski, T. F., F. Fallarino, A. Ashikari, and M. Sherman. 2001. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7:895s–901s.

    PubMed  CAS  Google Scholar 

  129. Lotze, M. T., B. Hellerstedt, L. Stolinski, T. Tueting, C. Wilson, D. Kinzler, H. Vu, J. T. Rubin, W. Storkus, H. Tahara, E. Elder, and T. Whiteside. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am 3:S109–114.

    PubMed  Google Scholar 

  130. Banchereau, J., A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A Rolland A, S. Taquet, S. Coquery, K. M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman, and J. Fay. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458.

    PubMed  CAS  Google Scholar 

  131. Lau, R., F. Wang, G. Jeffery, V. Marty, J. Kuniyoshi, E. Bade, M. E. Ryback, and J. Weber. 2001. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66–78.

    PubMed  CAS  Google Scholar 

  132. Chakraborty, N. G., J. R. Sporn, A. F. Tortora, S. H. Kurtzman, H. Yamase, M. T. Ergin, and B. Mukherji. 1998. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 47:58–64.

    PubMed  CAS  Google Scholar 

  133. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279–1288.

    PubMed  CAS  Google Scholar 

  134. Tjoa, B. A., P. A. Lodge, M. L. Salgaller, A. L. Boynton, and G. P. Murphy. 1999. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 49:117–128.

    PubMed  CAS  Google Scholar 

  135. Murphy, G. P., B. A. Tjoa, S. J. Simmons, M. K. Rogers, G. M. Kenny, and J. Jarisch. 2000. Higherdose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43:59–62.

    PubMed  CAS  Google Scholar 

  136. Lodge, P. A., L. Jones, R. A. Bader, G. P. Murphy, and M. L. Salgaller. 2000. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60:829–833.

    PubMed  CAS  Google Scholar 

  137. Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Radge, M. Rogers, A. Elgamal, G. M. Kenny, O. E. Cobb, R. C. Ireton, M. J. Troychak, M. L. Salgaller, and A. L. Boynton. 1999. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vacine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73–78.

    PubMed  CAS  Google Scholar 

  138. Burch, P. A., J. K. Breen, J. C. Buckner, D. A. Gastineau, J. A. Kaur, R. L. Laus, D. J. Padley, M. V. Peshwa, H. C. Pitot, R. L. Richardson, B. J. Smits, P. Sopapan, G. Strang, F. H. Valone, and S. Vuk-Pavlovic. 2000. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175–2182.

    PubMed  CAS  Google Scholar 

  139. Small, E. J., P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. Valone. 2000. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894–3903.

    PubMed  CAS  Google Scholar 

  140. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M. A. Maurice, C. D. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409–417.

    PubMed  CAS  Google Scholar 

  141. Rains, N., R. J. Cannan, W. Chen, and R. S. Stubbs. 2001. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48:347–351.

    PubMed  CAS  Google Scholar 

  142. Nair, S. K., M. Morse, D. Boczkowski, R. I. Cumming, L. Varsovic, E. Gilboa, and H. K. Lyerly. 2002. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540–549.

    PubMed  Google Scholar 

  143. Sadanaga, N., H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, T. Akiyoshi, and M. Mori. 2001. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277–2284.

    PubMed  CAS  Google Scholar 

  144. Brossart, P., S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108.

    PubMed  CAS  Google Scholar 

  145. Hernando, J. J., T.W. Park, K. Kubler, R. Offergeld, H. Schlebusch, and T. Bauknecht. 2002. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51:45–52.

    PubMed  CAS  Google Scholar 

  146. Kugler, A., G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. A. Muller, V. Becker, A. J. Gross, B. Hemmerlein, L. Kanz, G. A. Muller, and R. H. Ringert. 2000. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332–336.

    PubMed  CAS  Google Scholar 

  147. Holtl, L., C. Zelle-Rieser, H. Gander, C. Papesh, R. Ramoner, G. Bartsch, H. Rogatsch, A. L. Barsoum, J. H. Jr. Coggin, and M. Thurnher. 2002. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369–3376.

    PubMed  CAS  Google Scholar 

  148. Holtl, L., C. Rieser, C. Papesh, R. Ramoner, M. Herold, H. Klocker, C. Radmayr, A. Stenzl, G. Bartsch, and M. Thurnher. 1999. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777–782.

    PubMed  CAS  Google Scholar 

  149. Marten, A., D. Flieger, S. Renoth, S. Weineck, P. Albers, M. Compes, B. Schottker, C. Ziske, S. Engelhart, P. Hanfland, L. Krizek, C. Faber, A. Von Ruecker, S. Muller, T. Sauerbruch, and I. G. Schmidt-Wolf. 2002. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51:637–644.

    PubMed  Google Scholar 

  150. Rieser, C., R. Ramoner, L. Holtl, H. Rogatsch, C. Papesh, A. Stenzl, G. Bartsch, and M. Thurnher. 1999. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 63:151–159.

    PubMed  CAS  Google Scholar 

  151. Pecher, G., A. Haring, L. Kaiser, and E. Thiel. 2002. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669–673.

    PubMed  CAS  Google Scholar 

  152. Morse, M. A., Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M. E. Ryback, and H. K. Lyerly. 1999. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331–1338.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Grolleau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. J. Mulé
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Grolleau, A., Sloan, A., Mulé, J.J. (2005). Dendritic Cell-Based Vaccines for Cancer Therapy. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_8

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation